Enzyme, formerly known as Melon Protocol, is a decentralised open-source trading protocol built on the Ethereum blockchain. It specialises in asset management and cryptocurrency portfolio management. The platform aims to decentralise traditional asset management practices, providing users the ability to create, manage, and invest in various funds without traditional barriers to entry.
Enzyme operates on the Ethereum blockchain using a Proof of Stake (PoS) consensus mechanism. It utilises smart contracts to manage funds, execute transactions, and enforce rules, ensuring transparency and security. The platform features liquidity pooling, allowing users to combine assets for increased capital and trading opportunities. Enzyme also boasts a modular architecture that enables users to customise investment strategies. Additionally, off-chain oracles are used to provide real-time price information, and a minting and burning mechanism helps manage the MLN token supply.
Enzyme offers several use cases, including:
Enzyme's journey began in 2015, founded by Mona El Isa and Rito Trinkler under the Swiss company Melonport AG. It conducted its ICO in February 2017, raising $2.9 million in 10 minutes. The mainnet launched in February 2019, transitioning governance to the Enzyme Council, a DAO. In 2020, the protocol was rebranded from Melon Protocol to Enzyme Finance. The project integrates with numerous DeFi platforms and has formed partnerships to expand its ecosystem. The MLN token is an ERC-20 token used within the ecosystem for governance and fees, with an inflationary model and no maximum supply cap.